Issue link: https://htpgraphics.uberflip.com/i/116750
Commercialising the Inhibitor SCENARIOS Commercialising the Inhibitor As you may remember, Brian Hodgson and Ian Table have developed a new, effective Aromatose Inhibitor, for the treatment of breast cancer and IPP is keen to get involved in the development and marketing of the treatment. IPP has already made an initial approach to Lakeland regarding investing in the treatment. Lakeland is also eager to commercialise the results of Brian Hodgson's and Prof. Table's research as it sees lots of commercial potential. It also believes that the success of the treatment will enhance the reputation of Lakeland. Ideally, Lakeland is looking to enter into a licence agreement with IPP (giving IPP a licence to use the research results to develop the treatment further) that will allow Lakeland to have access to the state of the art resources that IPP has. Lakeland has already invested large sums of money into the research and development of the treatment. Brian and Prof. Table have been working on the matter for over two years. Lakeland would like this time and investment to be recognised in any licence agreement with IPP. IPP has indicated that it wants to see further tangible results before making financial commitments. Market research suggests that there would be a substantial return on IPP's investment in the treatment. Once the treatment is ready for sale, Lakeland would like to ensure that it reaps a fair proportion of the sales revenue for the drug. IPP has said that it does not want any of its competitors to become involved in the research and development of the treatment but it would like Brian Hodgson to continue working on the treatment, as he has considerable expertise in the field. Lakeland is keen to retain some use of the IP in the treatment. In particular, Lakeland wants to be able to use the IP in other areas, as it believes that the treatment may have applications in areas other than breast cancer treatment. The research is still in its early stages and it is likely that there will be scope for considerable improvements by Brian Hodgson and IPP's team. IPP has also said that it would like to be able to market the treatment on a worldwide scale. However, Lakeland is concerned that IPP does not have the resources to market the treatment on such a scale. Lakeland has heard that IPP has been approached by third parties who have offered to provide 28